Table of Contents
<< Previous Issue | Nov 2021 (Vol: 2021, Issue: 11) | Next Issue >> |
- Section: Licensing
-
Ironwood Begins to Rebolster its Pipeline with Cour’s Rare Disease Drug
- Section: Mergers & Acquisitions
-
Organon Advances Women’s Health Pipeline with US$954 M Forendo Acquisition
- Section: Research & Development
-
Takeda Broadens Gene Therapy Portfolio with Poseida’s Non-Viral Technologies
-
Hansoh Pharma Signs US$1.3 B RNAi Collaboration with Silence Therapeutics
-
Novartis Rejoins Protein Degradation Space with US$1.3 B Dunad Deal
-
Neurocrine Collaborates with Sosei Heptares for Neuropsychiatric Drugs